Stock Events

Stock Events

Ascendis Pharma A/S

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6AugExpected

Q4 2025

Q1 2026

Next

-0.54

2.84

6.22

9.61

Expected EPS

1.2012478911299342

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A710.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.

Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.

Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.

Vertex Pharmaceuticals

Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.

OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.

Ligand Pharmaceuticals

Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.

Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.

Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Show more...

CEO

Mr. Jan Moller Mikkelsen

Employees

1017

Country

Denmark

ISIN

DK0060615755

Listings

0 Comments

Share your thoughts

FAQ

What is Ascendis Pharma A/S stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Ascendis Pharma A/S stocks are traded under the ticker A710.MU.

When is the next Ascendis Pharma A/S earnings date?▼

Ascendis Pharma A/S is going to release the next earnings report on August 06, 2026.

What were Ascendis Pharma A/S earnings last quarter?▼

A710.MU earnings for the last quarter are 9.61 EUR per share, whereas the estimation was 0.16 EUR resulting in a +5,909.21% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does Ascendis Pharma A/S have?▼

As of May 09, 2026, the company has 1,017 employees.

In which sector is Ascendis Pharma A/S located?▼

Ascendis Pharma A/S operates in the Health & Wellness sector.

When did Ascendis Pharma A/S complete a stock split?▼

Ascendis Pharma A/S has not had any recent stock splits.

Where is Ascendis Pharma A/S headquartered?▼

Ascendis Pharma A/S is headquartered in Hellerup, Denmark.